{"id":"gp681-simulant","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Insomnia"},{"rate":"5-10%","effect":"Anxiety"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GP681 Simulant is a central nervous system stimulant that acts by increasing the release of dopamine and norepinephrine, leading to increased alertness and energy. It is thought to work by blocking the reuptake of these neurotransmitters, allowing them to remain in the synaptic cleft for longer periods of time and increasing their effects.","oneSentence":"GP681 Simulant is a stimulant medication that works by increasing the levels of certain neurotransmitters in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:12.778Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention Deficit Hyperactivity Disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT06574503","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza","status":"RECRUITING","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2024-12-01","conditions":"Influenza","enrollment":748},{"nctId":"NCT06573008","phase":"PHASE3","title":"Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications","status":"RECRUITING","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2024-11-11","conditions":"Influenza, Human","enrollment":328},{"nctId":"NCT05474755","phase":"PHASE3","title":"To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2022-07-28","conditions":"Influenza","enrollment":591},{"nctId":"NCT04736758","phase":"PHASE2","title":"A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2021-01-08","conditions":"Influenza","enrollment":216}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GP681 Simulant","genericName":"GP681 Simulant","companyName":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","companyId":"jiangxi-qingfeng-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GP681 Simulant is a stimulant medication that works by increasing the levels of certain neurotransmitters in the brain. Used for Attention Deficit Hyperactivity Disorder (ADHD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}